Life Technologies分销Advanced Cell Diagnostics公司RNAscope产品

 

2013年9月30日 Life Technologies分销Advanced Cell Diagnostics公司RNAscope产品

RNAscope是一种新型 RNA原位杂交技术，基于其独特的探针设计与背景抑制技术，并且融合传统RNA原位杂交技术与FISH技术的优点，使单个RNA的转录变得可视化，是目前最精准的RNA检测技术。
 

Life Technologies and Advanced Cell Diagnostics Sign Global Distribution Agreement

2013 September 30 | Posted by sagee@acdbio.com

CARLSBAD, CALIFORNIA, -- Sept. 30, 2013 -- Life Technologies Corporation (NASDAQ: LIFE) and Advanced Cell Diagnostics, Inc. (ACD), a leader in the field of molecular pathology and developer of cell and tissue-based analysis tools, today announced a global distribution agreement by which Life will distribute ACD’s fluorescent RNAscope® portfolio of probes and kits to the research market through its worldwide distribution network.

Life Technologies and Advanced Cell Diagnostics Sign Global Distribution Agreement

• Partnership makes Advanced Cell Diagnostics’ award-winning RNAscope® technology accessible to researchers worldwide
• Expands Life Technologies’ footprint in growing tissue analysis market  

Kits Support Growing RNA Biomarker Market, Cancer and Neurobiology Research 

RNA biomarker discovery and validation for the tissue analysis market is growing rapidly as the transition between research and the clinic continues to accelerate.  RNAscope® is quickly becoming a gold-standard technique to identify and validate RNA biomarkers in tissue for research, molecular diagnostics and companion diagnostics. Additionally, as cancer and neurobiology research continues to grow, there has been an explosion in the discovery of biomarkers identified from microarray and next-generation sequencing (NGS) technologies.  However, for many of these biomarkers, the specific cell types in the tissue that express them remain unknown, thereby limiting the ability to fully understand biological relevance.

“RNAscope complements our existing portfolio and solves long-standing technical hurdles researchers have encountered when studying heterogeneous samples,” says Siddhartha Kadia, Ph.D., President, Life Sciences at Life Technologies. “RNAscope’s ability to provide single-molecule RNA detection, while preserving tissue context makes it easy to pinpoint which biomarker is expressed in specific cells -- all at the convenience of a conventional fluorescence microscope.”

RNAscope features exceptional levels of sensitivity, specificity, and the ability to multiplex -- making it a breakthrough technology for localizing and measuring RNA in situ in unprecedented detail. It addresses many bottlenecks that arise due to lack of antibodies, and complements both NGS and qPCR methods by revealing the valuable, morphological context of newly identified biomarkers in both cells and complex tissues.

“Advanced Cell Diagnostics is delighted that RNAscope products will be introduced into multiple markets through Life Technologies extensive distribution networks,” said Yuling Luo, Founder, President & CEO, Advanced Cell Diagnostics. “Life Technologies has a legacy of introducing cutting-edge technologies to their customers and we are excited to have them represent RNAscope.”

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum—scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.